| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Aventis Pharma Research & Development, Dagenham Research Centre, Dagenham, Essex, United Kingdom Aventis Pharma Research & Development, Dagenham Research Centre, Dagenham, Essex, United Kingdom
Glucocorticoids (GCs) are the mainstay of asthma therapy; however, major side effects limit their therapeutic use. GCs influence the expression of genes either by transactivation or transrepression. The antiinflammatory effects of steroids are thought to be due to transrepression and the side effects, transactivation. Recently, a compound, RU 24858, has been identified that demonstrated dissociation between transactivation and transrepression in vitro. RU 24858 exerts strong AP-1 inhibition (transrepression), but little or no transactivation. We investigated whether this improved in vitro profile results in the maintenance of antiinflammatory activity (evaluated in the Sephadex model of lung edema) with reduced systemic toxicity (evaluated by loss in body weight, thymus involution, and bone turnover) compared with standard GCs. RU 24858 exhibits comparable antiinflammatory activity to the standard steroid, budesonide. However, the systemic changes observed indicate that transactivation events do occur with this GC with similar potency to the standard steroids. In addition, the GCs profiled showed no differentiation on quantitative osteopenia of the femur. These results suggest that in vitro separation of transrepression from transactivation activity does not translate to an increased therapeutic ratio for GCs in vivo or that adverse effects are a consequence of transrepression.
This article has been cited by other articles:
|
|
 |
|
  L. C. Hofbauer and M. Rauner Minireview: Live and Let Die: Molecular Effects of Glucocorticoids on Bone Cells Mol. Endocrinol., October 1, 2009; 23(10): 1525 - 1531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. De Bosscher and G. Haegeman Minireview: Latest Perspectives on Antiinflammatory Actions of Glucocorticoids Mol. Endocrinol., March 1, 2009; 23(3): 281 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dewint, V. Gossye, K. De Bosscher, W. Vanden Berghe, K. Van Beneden, D. Deforce, S. Van Calenbergh, U. Muller-Ladner, B. Vander Cruyssen, G. Verbruggen, et al. A Plant-Derived Ligand Favoring Monomeric Glucocorticoid Receptor Conformation with Impaired Transactivation Potential Attenuates Collagen-Induced Arthritis J. Immunol., February 15, 2008; 180(4): 2608 - 2615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Newton and N. S. Holden Separating Transrepression and Transactivation: A Distressing Divorce for the Glucocorticoid Receptor? Mol. Pharmacol., October 1, 2007; 72(4): 799 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. McMaster and D. W. Ray Modelling the glucocorticoid receptor and producing therapeutic agents with anti-inflammatory effects but reduced side-effects Exp Physiol, March 1, 2007; 92(2): 299 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Chivers, W. Gong, E. M. King, J. Seybold, J. C. Mak, L. E. Donnelly, N. S. Holden, and R. Newton Analysis of the Dissociated Steroid RU24858 Does Not Exclude a Role for Inducible Genes in the Anti-Inflammatory Actions of Glucocorticoids Mol. Pharmacol., December 1, 2006; 70(6): 2084 - 2095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Birrell, S. Wong, E. L. Hardaker, M. C. Catley, K. McCluskie, M. Collins, S. Haj-Yahia, and M. G. Belvisi I{kappa}B Kinase-2-Independent and -Dependent Inflammation in Airway Disease Models: Relevance of IKK-2 Inhibition to the Clinic Mol. Pharmacol., June 1, 2006; 69(6): 1791 - 1800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barnes Corticosteroid effects on cell signalling Eur. Respir. J., February 1, 2006; 27(2): 413 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Belvisi, D. S. Bundschuh, M. Stoeck, S. Wicks, S. Underwood, C. H. Battram, E.-B. Haddad, S. E. Webber, and M. L. Foster Preclinical Profile of Ciclesonide, a Novel Corticosteroid for the Treatment of Asthma J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 568 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rosen and J. N. Miner The Search for Safer Glucocorticoid Receptor Ligands Endocr. Rev., May 1, 2005; 26(3): 452 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-G. Bladh, J. Liden, K. Dahlman-Wright, M. Reimers, S. Nilsson, and S. Okret Identification of Endogenous Glucocorticoid Repressed Genes Differentially Regulated by a Glucocorticoid Receptor Mutant Able to Separate between Nuclear Factor-{kappa}B and Activator Protein-1 Repression Mol. Pharmacol., March 1, 2005; 67(3): 815 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Biggadike, I. Uings, and S. N. Farrow Designing Corticosteroid Drugs for Pulmonary Selectivity Proceedings of the ATS, December 1, 2004; 1(4): 352 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hochhaus New Developments in Corticosteroids Proceedings of the ATS, November 1, 2004; 1(3): 269 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Desmet, P. Gosset, B. Pajak, D. Cataldo, M. Bentires-Alj, P. Lekeux, and F. Bureau Selective Blockade of NF-{kappa}B Activity in Airway Immune Cells Inhibits the Effector Phase of Experimental Asthma J. Immunol., November 1, 2004; 173(9): 5766 - 5775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Schacke, A. Schottelius, W.-D. Docke, P. Strehlke, S. Jaroch, N. Schmees, H. Rehwinkel, H. Hennekes, and K. Asadullah Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects PNAS, January 6, 2004; 101(1): 227 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Kurucz, S. Toth, K. Nemeth, K. Torok, V. Csillik-Perczel, A. Pataki, C. Salamon, Z. Nagy, J. I. Szekely, K. Horvath, et al. Potency and Specificity of the Pharmacological Action of a New, Antiasthmatic, Topically Administered Soft Steroid, Etiprednol Dicloacetate (BNP-166) J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 83 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barnes and I. M. Adcock How Do Corticosteroids Work in Asthma? Ann Intern Med, September 2, 2003; 139(5_Part_1): 359 - 370. [Full Text] [PDF]
|
|
|
|
|
|
K. De Bosscher, W. Vanden Berghe, and G. Haegeman The Interplay between the Glucocorticoid Receptor and Nuclear Factor-{kappa}B or Activator Protein-1: Molecular Mechanisms for Gene Repression Endocr. Rev., August 1, 2003; 24(4): 488 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Coghlan, P. B. Jacobson, B. Lane, M. Nakane, C. W. Lin, S. W. Elmore, P. R. Kym, J. R. Luly, G. W. Carter, R. Turner, et al. A Novel Antiinflammatory Maintains Glucocorticoid Efficacy with Reduced Side Effects Mol. Endocrinol., May 1, 2003; 17(5): 860 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lasa, S. M. Abraham, C. Boucheron, J. Saklatvala, and A. R. Clark Dexamethasone Causes Sustained Expression of Mitogen-Activated Protein Kinase (MAPK) Phosphatase 1 and Phosphatase-Mediated Inhibition of MAPK p38 Mol. Cell. Biol., November 15, 2002; 22(22): 7802 - 7811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N.J. Vanacker, E. Palmans, R.A. Pauwels, and J.C. Kips Dose-related effect of inhaled fluticasone on allergen-induced airway changes in rats Eur. Respir. J., October 1, 2002; 20(4): 873 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.-B. Haddad, S. L. Underwood, D. Dabrowski, M. A. Birrell, K. McCluskie, C. H. Battram, M. Pecoraro, M. L. Foster, and M. G. Belvisi Critical Role for T Cells in Sephadex-Induced Airway Inflammation: Pharmacological and Immunological Characterization and Molecular Biomarker Identification J. Immunol., March 15, 2002; 168(6): 3004 - 3016. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Y. Almawi and O. K. Melemedjian Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor J. Leukoc. Biol., January 1, 2002; 71(1): 9 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Miura, R. Ouchida, N. Yoshikawa, K. Okamoto, Y. Makino, T. Nakamura, C. Morimoto, I. Makino, and H. Tanaka Functional Modulation of the Glucocorticoid Receptor and Suppression of NF-kappa B-dependent Transcription by Ursodeoxycholic Acid J. Biol. Chem., December 7, 2001; 276(50): 47371 - 47378. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
